Marc Fouassier

ORCID: 0000-0002-0964-0739
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Platelet Disorders and Treatments
  • Blood Coagulation and Thrombosis Mechanisms
  • Hemophilia Treatment and Research
  • Blood groups and transfusion
  • Venous Thromboembolism Diagnosis and Management
  • Heparin-Induced Thrombocytopenia and Thrombosis
  • Antiplatelet Therapy and Cardiovascular Diseases
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Complement system in diseases
  • Blood properties and coagulation
  • Coagulation, Bradykinin, Polyphosphates, and Angioedema
  • Blood disorders and treatments
  • Immunodeficiency and Autoimmune Disorders
  • Renal Diseases and Glomerulopathies
  • Hemoglobinopathies and Related Disorders
  • Lipoproteins and Cardiovascular Health
  • Acute Myeloid Leukemia Research
  • Hemostasis and retained surgical items
  • Cancer-related gene regulation
  • Erythrocyte Function and Pathophysiology
  • Sepsis Diagnosis and Treatment
  • Chronic Lymphocytic Leukemia Research
  • Food composition and properties
  • S100 Proteins and Annexins
  • Acute Myocardial Infarction Research

Centre Hospitalier Universitaire de Nantes
2015-2024

Nantes Université
2011-2024

Centre d'Investigation Clinique de Nantes
2013-2022

Hotel Dieu Hospital
2022

Laboratoire de Thermique et Energie de Nantes
2014

Centre Hospitalier Universitaire de Clermont-Ferrand
2002-2006

Service de la Santé Publique
2006

Centre Jean Perrin
1997-1998

Institut Pasteur
1924-1928

Excessive bleeding at surgery is a feared complication in patients with inherited platelet disorders. However, very few studies have evaluated the frequency of surgical these hemorrhagic We performed worldwide, multicentric, retrospective study to assess complications surgery, preventive and therapeutic approaches adopted, their efficacy disorders: Surgery Platelet disorders And Therapeutic Approach (SPATA) study. rated outcome 829 procedures carried out 423 well-defined forms 238 function...

10.3324/haematol.2016.160754 article EN cc-by-nc Haematologica 2017-04-06

Summary Thirty per cent of patients with mild haemophilia A (MHA) present markedly different FVIII: C level when assayed by one‐stage clotting and two‐stage chromogenic assays. It is, therefore, a real clinical challenge to predict the individual bleeding risk these patients. The aim work was study relationship between tendency results panel phenotypic genotypic tools. Thirty‐six MHA were included in this multicentre prospective study. severity symptoms evaluated using ISTH/SSC score....

10.1111/hae.12381 article EN Haemophilia 2014-02-12

Summary The platelet function analyser ( PFA ‐100) is a biological tool designed to explore primary haemostasis. This system has thus been widely demonstrated as reliable in detecting von Willebrand factor VWF ) deficiency. However, most studies were based on patients benefitting from regular medical care and accurate diagnosis, it would seem probable that the results somewhat optimistic, do not reflect its performances ‘real‐world’ situations. We have chosen study reliability of ‐100 for...

10.1111/hae.12653 article EN Haemophilia 2015-03-10

Antithrombin (AT) is a major physiological inhibitor of hemostasis. We report 22 novel antithrombin gene (SERPINC1) mutations associated with deficiency in 17 French and five German families. They were all present at the heterozygous state. Nine missense accounted for type I deficiency, defined by equally low activity antigen level. Most them (7/9) affected highly conserved serpin residues venous thrombosis occurring young age (before 32). One splice site, one nonsense mutation, three small...

10.1002/humu.9425 article EN Human Mutation 2006-01-01

In most laboratories, the severity of hemophilia A is assessed by factor VIII activity (FVIII:C) one-stage assay. However, comparisons these results with those two-stage assays can reveal discrepancies and suggest misdiagnosis.In this monocentric study, we measured FVIII:C two methods (one-stage chronometric chromogenic assays) in 307 (173 families) patients moderate/mild A. To compare results, used a chronometric/chromogenic ratio. Discrepancy was defined as ratio < 0.5 or > 1.5. We studied...

10.1111/j.1538-7836.2010.04174.x article EN publisher-specific-oa Journal of Thrombosis and Haemostasis 2010-12-17

BACKGROUND: Despite their usefulness in perioperative and acute care settings, factor-Xa inhibitor-specific assays are scarcely available, contrary to heparin anti-Xa assay. We assessed whether the assay can (1) be used as a screening test rule out apixaban, rivaroxaban, fondaparinux, danaparoid levels that contraindicate invasive procedures according current guidelines (&gt;30 ng·mL −1 , &gt;30 &gt;0.1 µg·mL IU·mL respectively), (2) quantify anticoagulant level if found significant, is, it...

10.1213/ane.0000000000005114 article EN Anesthesia & Analgesia 2020-08-20

We evaluated the use of turbidimetric HemosIL von Willebrand Factor (VWF) Activity assay (VWF:Act) on STA-R automated coagulometer (Stago, Asnières, France) for diagnosis disease (VWD). For this, we prospectively screened 268 patients. As a second part, retrospectively assayed 111 patients with well-defined VWD subtype. In first prospective study, demonstrate that in most cases VWD, VWF ristocetin cofactor activity (VWF:RCo) and VWF:Act are highly correlated but they both cannot be...

10.1177/1076029610379848 article EN Clinical and Applied Thrombosis/Hemostasis 2010-08-19

Major surgery is associated with an increased risk of venous thromboembolism (VTE), thus the application mechanical or pharmacologic prophylaxis recommended. The incidence VTE in patients inherited platelet disorders (IPD) undergoing surgical procedures unknown and no information on current use safety thromboprophylaxis, particularly low-molecular-weight-heparin these available. Here we explored approach to thromboprophylaxis thrombotic outcomes IPD at VTE-risk participating multicenter...

10.3324/haematol.2019.227876 article EN cc-by-nc Haematologica 2019-09-26

Germline mutations in runt-related transcription factor 1 (RUNX1), ETS variant 6 (ETV6) and ankyrin repeat domain 26 (ANKRD26) have been recognised as responsible of autosomal dominant inherited thrombocytopenia or platelet disorder, with an increased risk developing haematological malignancies (HM), mainly acute leukaemia (AL) myelodysplastic syndrome (MDS) (Duployez et al., 2016). Importantly, while all these disorders are associated abnormalities count functions, may be mild a bleeding...

10.1111/bjh.16543 article EN British Journal of Haematology 2020-02-27

We report on a 5-year-old boy with hyperzincemia and hypercalprotectinemia. Treatment began Tacrolimus at the age of 4 years 6 months. Despite an initial correction clinical biological symptoms, zincemia calprotectinemia progressively worsened secondary reappearance symptoms.Tacrolimus seems to have transient effect in treatment Hyperzincemia hyperprolactinemia.

10.1111/j.1651-2227.2008.01092.x article EN Acta Paediatrica 2008-12-03

Accurate assessment of platelet secretion is essential for the diagnosis inherited or acquired function disorders and more specifically in identifying δ-storage pool disease. Mepacrine, a fluorescent dye, accumulates δ-granules. The mepacrine flow cytometry (mepacrine FCM) assay has been used than half century clinical laboratory as diagnostic tool δ-granule disorders. requires small volume blood, can be performed thrombocytopenic patients, provides rapid content secretion, and, thus,...

10.1055/a-2413-2870 article EN Thrombosis and Haemostasis 2024-09-11

Abstract Introduction Acquired von Willebrand syndrome (AVWS) is a rare haemorrhagic disorder. The prophylaxis and treatment of bleeding before surgery are complex. Since 2018, new recombinant VWF (rVWF) concentrate that contains no factor VIII (FVIII) but high amount molecular weight multimers has been available in France. Aim To describe the real‐world experience using rVWF non‐surgical surgical procedures patients with AVWS. Methods Fifteen episodes seven 16 surgeries 10 were...

10.1111/hae.15098 article EN Haemophilia 2024-09-28
Coming Soon ...